-
Je něco špatně v tomto záznamu ?
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
B. Mlecnik, C. Bifulco, G. Bindea, F. Marliot, A. Lugli, JJ. Lee, I. Zlobec, TT. Rau, MD. Berger, ID. Nagtegaal, E. Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, A. Jouret-Mourin, A. Kartheuser, D....
Journal of clinical oncology.
2020 ;
38 (31) :
3638-3651.
[pub] 20200908
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc21011941
Online
Plný text
NLK
Free Medical Journals
od 2004 do Před 1 rokem
Open Access Digital Library
od 1999-01-01
PubMed
32897827
DOI
10.1200/jco.19.03205
Knihovny.cz E-zdroje
- MeSH
- adjuvantní chemoterapie MeSH
- antigeny CD3 metabolismus MeSH
- časové faktory MeSH
- CD8-pozitivní T-lymfocyty * metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru imunologie MeSH
- mikrosatelitní nestabilita MeSH
- míra přežití MeSH
- mutace MeSH
- nádory tračníku farmakoterapie genetika imunologie patologie MeSH
- počet lymfocytů MeSH
- prediktivní hodnota testů MeSH
- přežití bez známek nemoci MeSH
- protinádorové látky terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- tumor infiltrující lymfocyty MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
PURPOSE: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). METHODS: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The primary end point was TTR. Secondary end points were overall survival (OS), disease-free survival (DFS), prognosis in microsatellite stable (MSS) status, and predictive value of efficacy of chemotherapy. RESULTS: Patients with a high Immunoscore presented with the lowest risk of recurrence, in both cohorts. Recurrence-free rates at 3 years were 56.9% (95% CI, 50.3% to 64.4%), 65.9% (95% CI, 60.8% to 71.4%), and 76.4% (95% CI, 69.3% to 84.3%) in patients with low, intermediate, and high immunoscores, respectively (hazard ratio [HR; high v low], 0.48; 95% CI, 0.32 to 0.71; P = .0003). Patients with high Immunoscore showed significant association with prolonged TTR, OS, and DFS (all P < .001). In Cox multivariable analysis stratified by participating center, Immunoscore association with TTR was independent (HR [high v low], 0.41; 95% CI, 0.25 to 0.67; P = .0003) of patient's sex, T stage, N stage, sidedness, and microsatellite instability status. Significant association of a high Immunoscore with prolonged TTR was also found among MSS patients (HR [high v low], 0.36; 95% CI, 0.21 to 0.62; P = .0003). Immunoscore had the strongest contribution χ2 proportion for influencing survival (TTR and OS). Chemotherapy was significantly associated with survival in the high-Immunoscore group for both low-risk (HR [chemotherapy v no chemotherapy], 0.42; 95% CI, 0.25 to 0.71; P = .0011) and high-risk (HR [chemotherapy v no chemotherapy], 0.5; 95% CI, 0.33 to 0.77; P = .0015) patients, in contrast to the low-Immunoscore group (P > .12). CONCLUSION: This study shows that a high Immunoscore significantly associated with prolonged survival in stage III CC. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.
Center for Immuno Oncology University Hospital Siena Italy
Colorectal Surgery Department Istituto Nazionale Tumori IRCCS Fondazione G Pascale Napoli Italy
Curandis Laboratories Boston MA
Department of Biostatistics University of Texas MD Anderson Cancer Center Houston TX
Department of Immunology and Immunotherapy Kurume University School of Medicine Kurume Japan
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
Department of Medical Oncology University Hospital of Bern Bern Switzerland
Department of Molecular Microbiology and Immunology Oregon Health and Science University Portland OR
Department of Oncology Pathology Karolinska Institutet Karolinska University Stockholm Sweden
Department of Pathology and Laboratory Medicine University Health Network Toronto Ontario Canada
Department of Pathology Istituto Nazionale Tumori IRCCS Fondazione G Pascale Napoli Italy
Department of Pathology Memorial Sloan Kettering Cancer Center New York NY
Department of Pathology Providence Portland Medical Center Portland OR
Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan
Department of Surgery Kindai University School of Medicine Osaka sayama Japan
Equipe Labellisée Ligue Contre le Cancer Paris France
INSERM Laboratory of Integrative Cancer Immunology Paris France
Institute of Pathology University of Bern Bern Switzerland
IRCCS Istituto Nazionale Tumori Regina Elena Rome Italy
Princess Margaret Cancer Centre UHN Toronto Ontario Canada
Refuge Biotechnologies Menlo Park CA
The Gujarat Cancer and Research Institute Asarwa Ahmedabad India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011941
- 003
- CZ-PrNML
- 005
- 20210507103134.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1200/JCO.19.03205 $2 doi
- 035 __
- $a (PubMed)32897827
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mlecnik, Bernhard $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Inovarion, Paris, France
- 245 10
- $a Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer / $c B. Mlecnik, C. Bifulco, G. Bindea, F. Marliot, A. Lugli, JJ. Lee, I. Zlobec, TT. Rau, MD. Berger, ID. Nagtegaal, E. Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, A. Jouret-Mourin, A. Kartheuser, D. Léonard, C. Remue, JY. Wang, P. Bavi, MHA. Roehrl, PS. Ohashi, LT. Nguyen, S. Han, HL. MacGregor, S. Hafezi-Bakhtiari, BG. Wouters, GV. Masucci, EK. Andersson, E. Zavadova, M. Vocka, J. Spacek, L. Petruzelka, B. Konopasek, P. Dundr, H. Skalova, K. Nemejcova, G. Botti, F. Tatangelo, P. Delrio, G. Ciliberto, M. Maio, L. Laghi, F. Grizzi, T. Fredriksen, B. Buttard, L. Lafontaine, D. Bruni, A. Lanzi, C. El Sissy, N. Haicheur, A. Kirilovsky, A. Berger, C. Lagorce, C. Paustian, C. Ballesteros-Merino, J. Dijkstra, C. van de Water, S. van Lent-van Vliet, N. Knijn, AM. Muşină, DV. Scripcariu, B. Popivanova, M. Xu, T. Fujita, S. Hazama, N. Suzuki, H. Nagano, K. Okuno, T. Torigoe, N. Sato, T. Furuhata, I. Takemasa, K. Itoh, PS. Patel, HH. Vora, B. Shah, JB. Patel, KN. Rajvik, SJ. Pandya, SN. Shukla, Y. Wang, G. Zhang, Y. Kawakami, FM. Marincola, PA. Ascierto, BA. Fox, F. Pagès, J. Galon
- 520 9_
- $a PURPOSE: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). METHODS: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The primary end point was TTR. Secondary end points were overall survival (OS), disease-free survival (DFS), prognosis in microsatellite stable (MSS) status, and predictive value of efficacy of chemotherapy. RESULTS: Patients with a high Immunoscore presented with the lowest risk of recurrence, in both cohorts. Recurrence-free rates at 3 years were 56.9% (95% CI, 50.3% to 64.4%), 65.9% (95% CI, 60.8% to 71.4%), and 76.4% (95% CI, 69.3% to 84.3%) in patients with low, intermediate, and high immunoscores, respectively (hazard ratio [HR; high v low], 0.48; 95% CI, 0.32 to 0.71; P = .0003). Patients with high Immunoscore showed significant association with prolonged TTR, OS, and DFS (all P < .001). In Cox multivariable analysis stratified by participating center, Immunoscore association with TTR was independent (HR [high v low], 0.41; 95% CI, 0.25 to 0.67; P = .0003) of patient's sex, T stage, N stage, sidedness, and microsatellite instability status. Significant association of a high Immunoscore with prolonged TTR was also found among MSS patients (HR [high v low], 0.36; 95% CI, 0.21 to 0.62; P = .0003). Immunoscore had the strongest contribution χ2 proportion for influencing survival (TTR and OS). Chemotherapy was significantly associated with survival in the high-Immunoscore group for both low-risk (HR [chemotherapy v no chemotherapy], 0.42; 95% CI, 0.25 to 0.71; P = .0011) and high-risk (HR [chemotherapy v no chemotherapy], 0.5; 95% CI, 0.33 to 0.77; P = .0015) patients, in contrast to the low-Immunoscore group (P > .12). CONCLUSION: This study shows that a high Immunoscore significantly associated with prolonged survival in stage III CC. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a antigeny CD3 $x metabolismus $7 D017252
- 650 12
- $a CD8-pozitivní T-lymfocyty $x metabolismus $7 D018414
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a nádory tračníku $x farmakoterapie $x genetika $x imunologie $x patologie $7 D003110
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 _2
- $a tumor infiltrující lymfocyty $7 D016246
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikrosatelitní nestabilita $7 D053842
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a lokální recidiva nádoru $x imunologie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bifulco, Carlo $u Department of Pathology, Providence Portland Medical Center, Portland, OR
- 700 1_
- $a Bindea, Gabriela $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a Marliot, Florence $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Lugli, Alessandro $u Institute of Pathology, University of Bern, Bern, Switzerland
- 700 1_
- $a Lee, J Jack $u Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX
- 700 1_
- $a Zlobec, Inti $u Institute of Pathology, University of Bern, Bern, Switzerland
- 700 1_
- $a Rau, Tilman T $u Institute of Pathology, University of Bern, Bern, Switzerland
- 700 1_
- $a Berger, Martin D $u Department of Medical Oncology, University Hospital of Bern, Bern, Switzerland
- 700 1_
- $a Nagtegaal, Iris D $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a Vink-Börger, Elisa $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a Hartmann, Arndt $u Department of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Geppert, Carol $u Department of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Kolwelter, Julie $u Department of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Merkel, Susanne $u Department of Surgery, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Grützmann, Robert $u Department of Surgery, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Van den Eynde, Marc $u Institut Roi Albert II, Department of Medical Oncology Cliniques Universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Jouret-Mourin, Anne $u Department of Pathology, Cliniques Universitaires St-Luc and Institut de Recherche Clinique et Experimentale (Pole GAEN), Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Kartheuser, Alex $u Institut Roi Albert II, Department of Digestive Surgery, Cliniques Universitaires St-Luc Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Léonard, Daniel $u Institut Roi Albert II, Department of Digestive Surgery, Cliniques Universitaires St-Luc Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Remue, Christophe $u Institut Roi Albert II, Department of Digestive Surgery, Cliniques Universitaires St-Luc Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Wang, Julia Y $u Curandis Laboratories, Boston, MA $u Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Bavi, Prashant $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Roehrl, Michael H A $u Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
- 700 1_
- $a Ohashi, Pamela S $u Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada
- 700 1_
- $a Nguyen, Linh T $u Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada
- 700 1_
- $a Han, SeongJun $u Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada
- 700 1_
- $a MacGregor, Heather L $u Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada
- 700 1_
- $a Hafezi-Bakhtiari, Sara $u Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada
- 700 1_
- $a Wouters, Bradly G $u Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada
- 700 1_
- $a Masucci, Giuseppe V $u Department of Oncology-Pathology, Karolinska Institutet, Karolinska University, Stockholm, Sweden
- 700 1_
- $a Andersson, Emilia K $u Department of Oncology-Pathology, Karolinska Institutet, Karolinska University, Stockholm, Sweden
- 700 1_
- $a Zavadova, Eva $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Spacek, Jan $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Konopasek, Bohuslav $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Skalova, Helena $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Nemejcova, Kristyna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Botti, Gerardo $u Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
- 700 1_
- $a Tatangelo, Fabiana $u Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
- 700 1_
- $a Delrio, Paolo $u Colorectal Surgery Department, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
- 700 1_
- $a Ciliberto, Gennaro $u IRCCS Istituto Nazionale Tumori "Regina Elena", Rome, Italy
- 700 1_
- $a Maio, Michele $u Center for Immuno-Oncology, University Hospital, Siena, Italy
- 700 1_
- $a Laghi, Luigi $u Department of Medicine and Surgery, University of Parma, and Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
- 700 1_
- $a Grizzi, Fabio $u Department of Immunology and Inflammation, Humanitas Clinical and Research Center, Rozzano, Milan, Italy and Humanitas University, Rozzano, Milan, Italy
- 700 1_
- $a Fredriksen, Tessa $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a Buttard, Bénédicte $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a Lafontaine, Lucie $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a Bruni, Daniela $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a Lanzi, Anastasia $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 700 1_
- $a El Sissy, Carine $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Haicheur, Nacilla $u Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Kirilovsky, Amos $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Berger, Anne $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Digestive Surgery Department, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Lagorce, Christine $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Department of Pathology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Paustian, Christopher $u Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR
- 700 1_
- $a Ballesteros-Merino, Carmen $u Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR
- 700 1_
- $a Dijkstra, Jeroen $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a van de Water, Carlijn $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a van Lent-van Vliet, Shannon $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a Knijn, Nikki $u Department of Pathology, Radboud Institute of Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
- 700 1_
- $a Muşină, Ana-Maria $u University of Medicine and Pharmacy "Grigore T. Popa" Iaşi, Department of Surgical Oncology, Regional Institute of Oncology, Iaşi, Romania
- 700 1_
- $a Scripcariu, Dragos-Viorel $u University of Medicine and Pharmacy "Grigore T. Popa" Iaşi, Department of Surgical Oncology, Regional Institute of Oncology, Iaşi, Romania
- 700 1_
- $a Popivanova, Boryana $u Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
- 700 1_
- $a Xu, Mingli $u Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
- 700 1_
- $a Fujita, Tomonobu $u Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
- 700 1_
- $a Hazama, Shoichi $u Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University School of Medicine, Yamaguchi, Japan
- 700 1_
- $a Suzuki, Nobuaki $u Department of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
- 700 1_
- $a Nagano, Hiroaki $u Department of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
- 700 1_
- $a Okuno, Kiyotaka $u Department of Surgery, Kindai University, School of Medicine, Osaka-sayama, Japan
- 700 1_
- $a Torigoe, Toshihiko $u Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
- 700 1_
- $a Sato, Noriyuki $u Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
- 700 1_
- $a Furuhata, Tomohisa $u Department of Surgery, Surgical Oncology, and Science, Sapporo Medical University School of Medicine, Sapporo, Japan
- 700 1_
- $a Takemasa, Ichiro $u Department of Surgery, Surgical Oncology, and Science, Sapporo Medical University School of Medicine, Sapporo, Japan
- 700 1_
- $a Itoh, Kyogo $u Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
- 700 1_
- $a Patel, Prabhu S $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Vora, Hemangini H $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Shah, Birva $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Patel, Jayendrakumar B $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Rajvik, Kruti N $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Pandya, Shashank J $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Shukla, Shilin N $u The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, India
- 700 1_
- $a Wang, Yili $u Institute of Cancer Research, Center of Translational Medicine, Health Science Center of Xi'an Jiaotong University, Xian, China
- 700 1_
- $a Zhang, Guanjun $u Institute of Cancer Research, Center of Translational Medicine, Health Science Center of Xi'an Jiaotong University, Xian, China
- 700 1_
- $a Kawakami, Yutaka $u Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
- 700 1_
- $a Marincola, Francesco M $u Refuge Biotechnologies, Menlo Park, CA
- 700 1_
- $a Ascierto, Paolo A $u Melanoma, Cancer Immunotherapy, and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy
- 700 1_
- $a Fox, Bernard A $u Department of Pathology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France $u Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR
- 700 1_
- $a Pagès, Franck $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France $u Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
- 700 1_
- $a Galon, Jérôme $u INSERM, Laboratory of Integrative Cancer Immunology, Paris, France $u Equipe Labellisée Ligue Contre le Cancer, Paris, France $u Centre de Recherche des Cordeliers, Sorbonne Université, Sorbonne Paris Cité, Université de Paris, Paris, France
- 773 0_
- $w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 31 (2020), s. 3638-3651
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32897827 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507103131 $b ABA008
- 999 __
- $a ok $b bmc $g 1650341 $s 1132320
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 38 $c 31 $d 3638-3651 $e 20200908 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
- LZP __
- $a Pubmed-20210420
